NASDAQ: PTCT · Life Sciences · 10 alerts · CIK 1070081
Share price
$60.97Close, Nov 16
Market cap
$5.09B
Shares outstanding
83.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PTC Therapeutics, Inc. filings on SEC EDGAR ↗
PTC Therapeutics announced that its Board of Directors has authorized a share repurchase program to buy back up to $500 million of its common stock. The repurchases will be conducted at management's discretion through open-market or privately negotiated transactions based on market conditions.
For the nine months ended September 30, 2026, PTC Therapeutics reported total revenues of $990.9 million and net income of $29.0 million, a significant decrease from the $817.6 million net income in the prior year period which was bolstered by high collaboration revenue. The company's balance sheet remains strong with $2.1 billion in cash, cash equivalents, and marketable securities, though it maintains a total stockholders' deficit of $191.2 million.
PTC Therapeutics reported record third-quarter 2026 financial results, with total revenue reaching $358 million, driven by $182 million in sales from the Sephience launch. The company raised its full-year 2026 revenue guidance to a range of $1.29 billion to $1.32 billion and expects to complete its BLA submission for the ST-920 Fabry disease gene therapy in Q4 2026.
“We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”